Aurinia Pharmaceuticals (AUPH) Cash from Operations Growth (1y) (2021 - 2026)
Aurinia Pharmaceuticals (AUPH) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Aurinia Pharmaceuticals | 2.04 Bn | 1.66 Bn | 71.20 Mn | 2,404.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,404.62% |
| Dec 31, 2025 | 51.65% |
| Sep 30, 2025 | 161.02% |
| Jun 30, 2025 | 179.25% |
| Mar 31, 2025 | 106.99% |
| Dec 31, 2024 | 110.41% |
| Sep 30, 2024 | 228.26% |
| Jun 30, 2024 | 660.62% |
| Mar 31, 2024 | 41.28% |
| Dec 31, 2023 | 36.96% |
| Sep 30, 2023 | 13.57% |
| Jun 30, 2023 | 89.86% |
| Mar 31, 2023 | 32.25% |
| Dec 31, 2022 | 140.31% |
| Sep 30, 2022 | 61.83% |
| Jun 30, 2022 | 26.61% |
| Mar 31, 2022 | 12.69% |
| Dec 31, 2021 | -909.05% |
| Sep 30, 2021 | -41.65% |
| Jun 30, 2021 | -72.33% |